36 results about "Medical genetics" patented technology

The invention provides a kit and method for detecting mutation of a thalassemia-related gene and a use thereof and relates to the technical field of medical genetics. The kit for detection is used for detecting many types of patients such as people needing premarital checkup, people in gestation, newborns, people in a zone having high incidence of thalassemia and people having thalassemia family heredity history, can realize accurate, comprehensive, visual and simple detection of mutation of a thalassemia-related gene, has a detection mutation range comprising HBA1, HBA2 and HBB genes in the genome and neighbouring zones and has the characteristics of simpleness, accuracy, good repeatability and promotion and use easiness.

The invention provides a fluorescently-labeled X-InDel locus composite amplification system. By means of the system, eighteen insertion-deletion genetic polymorphism loci on an X chromosome can be compositely amplified, wherein the eighteen loci are respectively labeled with three fluoresceins FAM, HEX and TAMRA. The composite amplification system is high in sensitivity and individual identification rate, is high in polymorphism, is good in stability and repeatability, is accurate in typing results and can satisfy a practical requirement. A kit can be manufactured on the basis of the composite amplification system, can be used for paternity test, dyad paternity test, grandparent and grandchild test, sibling test and individual identification. New technologies can be provided for the fields such as anthropology, medical genetics and the like.

The invention discloses a construction scheme of artificially transforming human type 5 adenovirus (Ad5), and a specific application of a novel oncolytic adenovirus construct obtained by the scheme in tumor treatment, and belongs to the technical field of medical genetic engineering. A recombinant adenovirus construct obtained by PCR amplification site-directed deletion, enzyme digestion, ligation, cloning, homologous recombination, transfection, adenovirus monoclonal purification, etc., its technical characteristics are: Ad5 genome E1A conserved sequence 2 27 bases were deleted in the (CR2) region; 29477-29714nt of the ADP gene in the E3 region was deleted; and the full-length coding sequence (1131bp) of the HSV-TK gene was inserted in the deleted region. This construct is a new type of oncolytic adenoviral vector with higher tumor selective replication ability, which utilizes the suicide gene function of HSV-TK and the double killing effect of oncolytic virus to dissolve tumor cells, and has great potential in the biological treatment of tumors. Unique practical value.

The invention provides a method for detecting a nervous system and multiple intelligences interpretated by dermatoglyphic. The method covers the fields of medical genetic dermatoglyphic, neuroscience and behavior science. Connection between dermatoglyphic and the nervous system is integrated by dermatoglyphic features by different geneogenous patients with neurologic deficit. For example, if a central chief execution weaker is projected by a left thumb by dermatoglyphic detecting, the invention shows the same situations appearing in the fields of autism, sense organ disorder, attention deficit disorder, attention deficit hyperactivity disorder, etc. Weakened moral function causes low stress tolerance and depression trait, which has important reference value for evaluating the possibility of suffering from mental disorder. And the attention deficit disorder also causes learning disability easily. Therefore, the method for detecting the nervous system and multiple intelligences interpretated by dermatoglyphic has higher utility value on the whole use.

The invention discloses a proposal for constructing novel oncocytic adenovirus of selectively closed tumor STAT3 obtained by manual reconstruction of human 5 type adenovirus (Ad5), and particular application of a recombined adenovirus constructor in tumor treatment, and belongs to the technical field of medical genetic engineering. By techniques of PCR enlarging fixed point deletion, enzyme cutting, connection, cloning, homologous recombination, transfection, single cloning purification of adenovirus and the like, the recombination adenovirus constructor is obtained. The technical characteristics comprise that 27 basic groups are deleted in an E1A conservative sequence 2(CR2) zone of Ad5 genome; 29477 to 29714nt in an E3 zone of ADP gene are deleted; and partial STAT cDNA segments are oppositely inserted in the deletion zones. The constructor is a novel oncocytic adenovirus vector with higher tumor selective copy capability. The constructor has unique practical values in biological treatment of tumor, and also provides a reasonable gene target point specificity treatment mode for the genetic treatment of tumor.

The invention relates to a method for correcting human genome damage through micro nutrient substances according to the genetic background and belongs to the technical field of nutrition genomics and medical genetics application. The method comprises the steps that peripheral blood of an individual is sampled, the levels of folate of the blood, serum VB12 and serum Hcy are detected, nuclear DNA is extracted, the MTHFR C677T and A1298C genetypes and the genome damage condition of the individual are combined, and micro nutrient substance intervention suggestions are given to the individual with the high genome damage according to reference values (the folate of erythrocyte is higher than 700 nM, the serum folate is higher than 34 nM, the serum VB12 is higher than 300 pM, and the serum Hcy is lower than 8 micrometers) at which various blood micro nutrient substances maintain the stability of genomes, so that the heredity damage of the individual is corrected, and the stability of the genomes is maintained. The strategy is beneficial to preventing cardiovascular diseases and reducing the risk factor of genome damage related diseases.

The invention discloses a SiRNA (small interfering ribose nucleic acid) for inhibiting homosapiens chromosome 2 open reading frame 3(C2 or f3) (GCF) gene expression, which belongs to the field of medical genetic engineering. Deoxyribose nucleic acid (DNA) for an encoding SiRNA is selected from arbitrary group of (a), (b) and (c): (a) a base sequence of a positive-sense strand is shown as SEQ ID No.1, and the base sequence of an antisense strand is shown as SEQ ID No.2; (b) the base sequence of the positive-sense strand is shown as SEQ ID No.3, and the base sequence of the antisense strand is shown as SEQ ID No.4; and (c) the base sequence of the positive-sense strand is shown as SEQ ID No.5, and the base sequence of the antisense strand is shown as SEQ ID No.6. The invention further discloses a recombinant plasmid which comprises the DNA of the encoding SiRNA and a GCF-shRNA-HeLaCGMCC (China general microbiological culture collection center) No.5821, and a cell line has high RNA interfering efficiency, strong specificity and no toxic and side effects and can effectively inhibit GCF gene expression. The SiRNA for inhibiting GCF gene expression, the recombinant plasmid and the GCF-shRNA-HeLa monoclonal cell can also be used for preparing medicines for treating cervical cancer.

The invention relates to a detection method and chip for a susceptibility gene of dilatant and hypertrophic cardiomyopathy. Based on a target region capture high-throughput sequencing technology, a group of specific and effective gene set associated with DCM/HCM cardiovascular disease is selected and is subjected to high-throughput capture and sequencing analysis by a self-developed probe library-building capture process and analysis software, so as to find out variation conditions of genetic level cardiovascular disease-related genes, especially DCM/HCM genes and the like, by gene means to screen the susceptibility gene. The screening result refers to the guidelines of the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP) to interpret variations. Compared with conventional high-throughput sequencing, a kit has the advantages of high pertinence, low cost, fast flow and the like.

The invention relates to an EBV transfected chimera quality-control cell for antenatal diagnosis and a preparation method thereof, and belongs to medical genetics. The invention is mainly characterized in that the preparation method comprises: taking residual living cells which are used for chromosomal disease diagnosis as needed by clinical diagnosis and treatment and are definitely diagnosed to have common numerical abnormalities of chromosomes, separating lymphocytes, culturing in an RPMI-1640 culture solution containing cyclosporin A and EBV under a condition of 37 DEG C and 5% CO2, allowing B lymphocytes to form immortalized lymphoblast lines with infinite reproduction capability, performing subculture amplification to reach a desired amount, then cryopreserving the cell lines, mixing the cell lines according to a required ratio for quality control when in use so as to prepare each original cell line with only one type of numerical abnormalities of chromosomes into a chimera quality-control cell line which has a specific ratio and multiple combinations of numerical abnormalities of chromosomes, is universal for various testings, and is more difficult for differential diagnosis. Original cells are easily available, and waste excessive cells are prepared artificially into practical and effective quality-control cells which can be amplified as needed.

In synthetic polynucleotides, the sensitivity and specificity of synthetic polynucleotides can be improved by protecting the 3' end of the oligonucleotide and then using it as a primer. Protecting the 3' end of the polynucleotide prevents non-specific chain elongation. Then, when the temperature is raised, the blocking group is removed under the action of a thermostable enzyme, thereby performing template-specific polynucleotide synthesis. The invention also provides an oligonucleotide with a blocking group at the 3' end and a thermostable enzyme capable of removing the blocking group at high temperature. The components and methods of the invention are very useful in a variety of DNA/RNA amplification and analysis techniques, including medical genetic research, diagnosis, pathogen detection, forensic science, and animal and plant genetic applications.

The invention discloses a sgRNA targeting sequence specifically targeting the mouse G6pc gene and application thereof, and belongs to the technical field of medical genetics and molecular biology. Thenucleotide sequence corresponding to the sgRNA contains the sequence as shown in SEQ ID NO. 2. The invention also discloses a method for editing the mouse G6pc gene by using the above sgRNA targetingsequence specifically targeting the mouse G6pc gene. The sgRNA targeting sequence of the invention can mediate the Cas9 protein and efficiently cut target DNA, and further can be used for editing themouse G6pc gene to affect the function of mouse G6pc gene encoding protein. The sgRNA targeting sequence can efficiently realize targeting by a CRISPR/Cas9 system with an efficiency of 100%.

The invention discloses an oncolytic adenovirus recombinant carrying TMTP1 and tBid as well as a construction method and application of the oncolytic adenovirus recombinant, and belongs to the technical field of medical genetic engineering. According to the invention, 27 basic groups in a 920nt-946nt region are deleted in a second region of an E1A conserved sequence of a human type 5 adenovirus gene, a gene sequence for coding a tumor targeting peptide TMTP1 is inserted in a 19641nt-19655nt region of a Hexon hypervariable region 5, an E3 region is deleted in a 29477nt-29714nt region of an ADP gene to form a deletion region, a gene sequence of a mitochondrial apoptosis peptide tBid is inserted in the deletion region, and a Cla1 enzyme cutting site is introduced. The invention also discloses a construction method and application of the oncolytic adenovirus recombinant. The oncolytic adenovirus recombinant carrying the TMTP1 and the tBid disclosed by the invention has an ideal targeting effect and a strong killing effect.

The invention belongs to the technical field of medical genetics, and relates to a SMN gene main transition region DNA amplification method. The technical problem to be solved is conventional DNA of amain transition region of a SMN gene and the DNA amplification method containing methylation information. The technical scheme is characterized in that a DNA amplification primer is designed, and a 3' end of the primer does not contain nucleotide C in a corresponding genome, so that PCR amplification can be prevented from being affected by potential methylation at the end of the corresponding transition region. The stable and optimized PCR reaction conditions can be found. The main purpose of the method comprises screening for polymorphic sites of the molecular background of gene conversion in the main transition region of the SMN gene, and providing a basis for the methylation of CpG site potentially associated with DNA hypomethylation and SMN gene transformation. The method provides a prerequisite for the study of mechanisms that can relatively reduce the condition of SMA, and can be applied to find gene therapy targets.

The invention belongs to the field of molecular biology and genetics, and particularly discloses a constructing method of a genetic marker reference system for group differentiating and identification, and a genetic marker reference system. The constructing method comprises the steps of performing data segmentation on genetic marker data, performing genetic marker selection, or filtering the segmented data according to the condition, or performing integration optimization on the selected genetic marker. The method according to the invention can successfully reduce computing complexity from O(2n) to O(n2). In combination with some simple pre-screening strategies, the method according to the invention can process the whole genome data of thousands of persons to ten thousands of person, and selects the genetic marker reference system. In actual application, the method can be used for selecting the reference system which has preset accuracy (such as 95% or 99%) and comprises relatively small number of genetic markers according to the actual requirement. The characteristics have an important application value in legal examiner or medical genetic researching.

The invention discloses an oncolytic adenovirus recombinant carrying TMVP1 and tBid as well as a construction method and application of the oncolytic adenovirus recombinant, and belongs to the technical field of medical genetic engineering. According to the invention, 27 basic groups in a 920nt-946nt region are deleted in a second region of an E1A conserved sequence of a human type 5 adenovirus gene, a gene sequence for coding a tumor targeting peptide TMVP1 is inserted in a 19641nt-19655nt region of a Hexon hypervariable region 5, an E3 region is deleted in a 29477nt-29714nt region of an ADP gene to form a deletion region, a gene sequence of a mitochondrial apoptosis peptide tBid is inserted in the deletion region, and a Cla1 enzyme cutting site is introduced. The invention also discloses a construction method and application of the oncolytic adenovirus recombinant. The oncolytic adenovirus recombinant carrying the TMVP1 and the tBid disclosed by the invention has an ideal targeting effect and a strong killing effect.

The invention discloses an oncolytic adenovirus recombinant carrying TMTP1 and HSV-TK as well as a construction method and application of the oncolytic adenovirus recombinant, and belongs to the technical field of medical genetic engineering. According to the invention, 27 basic groups in a 920-946nt region are deleted in a second region of an E1A conserved sequence of a human type 5 adenovirus gene, a gene sequence for coding a tumor targeting peptide TMTP1 is inserted in a 19641-19655nt region of a Hexon hypervariable region 5, an E3 region is deleted in a 29477th-29714nt region of an ADP gene to form a deletion region, a full-length coding sequence for coding an HSV-TK gene is inserted in the deletion region, and a Cla1 enzyme cutting site is introduced. The invention also discloses a construction method and application of the oncolytic adenovirus recombinant. The oncolytic adenovirus recombinant carrying the TMTP1 and the HSV-TK disclosed by the invention has an ideal targeting effect and a strong killing effect.

The invention discloses an sgRNA guide sequence of a specific targeting mouse Gaa gene and an application thereof, which belong to the technical field of medical genetics and molecular biology. A nucleotide sequence corresponding to the sgRNA is any one of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. The invention also discloses a method for editing the mouse Gaa gene by using the sgRNA guide sequence of the specific targeting mouse Gaa gene. The sgRNA guide sequence disclosed by the invention can mediate Cas9 protein to efficiently cut target DNA, so that the sgRNA guide sequence is used forediting the mouse Gaa gene to influence the function of encoding protein of the mouse Gaa gene. According to the sgRNA guide sequence, efficient targeting can be achieved through a CRISPR/Cas9 system,and the efficiency is 100%.